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Low calorie commercial sugar is a sensitive marker of
glomerular filtration rate
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Low calorie commercial sugar is a sensitive marker of glomeru-
lar filtration rate.
Background. Glomerular filtration rate (GFR) in humans
and animals might be determined with precision by measuring
the clearance of an ideal marker, such as inulin. However, the
use of inutest, an inulin analog, is limited by its cost and accessi-
bility. The present study tested whether low calorie commercial
sugar (LC sugar) can be used to measure GFR during normal
and renal dysfunction.
Methods. Two groups of 6 male Wistar rats weighing 300 to
350 g were included. One group was treated with a daily dose of
cyclosporine (CsA) 30 mg/kg subcutaneously for 7 days and the
other group was formed by nontreated control rats. In one half
of each group, GFR was evaluated by using inutest and in the
other half by using LC sugar. GFR was also evaluated by using
a wide LC sugar plasma concentration range in an additional
group.
Results. In nontreated rats, the mean GFR evaluated with LC
sugar was 2.2 ± 0.1 mL/min. This value is equal to that obtained
with inutest: 2.3 ± 0.1 mL/min. CsA administration produced
a significant reduction of renal blood flow and renal function.
The GFR reduction induced by CsA was similarly determined
by both LC sugar and inutest to be at 1.0 ± 0.2 and 1.1 ± 0.2
mL/min (P = NS), respectively. In addition, GFR did not change
when LC sugar plasma concentration gradually increased.
Conclusion. Our results show that in both normal and patho-
physiologic conditions, LC sugar is a good marker of GFR sim-
ilar to the gold standard inutest.
Quantifying glomerular filtration rate (GFR) with sen-
sitive and specific techniques allows testing the extent and
prognosis of renal dysfunction and contributes substan-
tially to our understanding of a variety of renal disease
mechanisms, as well as potentially increasing the accuracy
of diagnosis and directing appropriate therapy. More-
over, GFR estimation is a powerful tool in experimental
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models of renal disease that not only evaluates renal vi-
ability or success of new therapies, but also for studying
mechanisms of renal injury.
Accurate renal function is evaluated through the mea-
surement of the renal clearance of an ideal filtration
marker. Inulin, an exogenous marker, is the only com-
pound that is neither toxic nor metabolized, the excretion
of which occurs exclusively by glomerular filtration, with
no tubular reabsorption or secretion. Therefore, inulin
clearance provides the most accurate method to mea-
sure GFR, as well as for evaluating single nephron GFR
by micropuncture techniques, and is considered as the
“gold standard” of renal function evaluation [1–6]. How-
ever, inulin solubility is low and tends to form precipitates
in urine and plasma, complicating samples handling and
inulin concentration determination [7, 8]. The introduc-
tion of polyfructosan (inutest), a more soluble compound,
avoided this problem [6, 9–13]; nevertheless, the use of in-
utest is limited due to its high cost and because it is only
produced in some European countries. Finally, a third
alternative to accurately evaluate GFR is the use of radi-
olabeled markers, such as [3H]inulin, [51Cr]EDTA, and
p-aminohippurate [10, 14–17], but these strategies have
also a number of disadvantages associated with their cost
and safety issues that are inherent to the use of radioiso-
topes, including the fact that in the case of [3H], isotope
concentration declines, resulting in underestimation of
GFR [18].
In order to have an inexpensive and accessible exoge-
nous GFR marker, we reasoned that the artificial sweet-
ener LC sugar (http://www.metco.com.mx/azucarbc2.
html); a low calorie sugar made of sucrose, that is widely
available at very low cost, could be a GFR marker if
possessing similar inulin properties such as being freely
eliminated, nonsecreted, or tubular reabsorbed, as well as
being neither toxic nor metabolized. To test this hypothe-
sis, glomerular filtration rate in nontreated rats and in rats
with certain degree of renal failure induced by acute CsA
nephrotoxicity was evaluated by using LC sugar and com-
pared with inutest as a gold standard. Our results show
that LC sugar is an accessible, sensitive, and inexpensive
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marker of GFR similar to inutest or inulin markers, in
both normal and pathophysiologic conditions.
METHODS
In order to evaluate if low calorie sugar (LC sugar) is
a sensitive marker of glomerular filtration rate, LC sugar
GFR was determined in nontreated rats and in rats with
renal dysfunction induced by cyclosporine administra-
tion. The values were compared with GFR determined
by inutest. Two groups of 6 or 7 male Wistar rats weigh-
ing 300 to 350 g fed with standard chow diet were included
in the study. One was treated with a daily dose of CsA
30 mg/kg subcutaneously for 7 days and the other group
was formed by nontreated rats. In one half of each group,
GFR was evaluated by using inutest and in the other half
by using LC sugar. In addition, one group of 6 rats was
included to evaluate the linearity of LC sugar excretion
by using different concentrations that ranged from 5% to
12.5%. All procedures followed were in accordance with
our institutional guidelines.
Functional studies
All animals were placed in metabolic cages and urine
that was spontaneously voided during every 24 hours
was collected. Serum and urine creatinine concentration
was measured with an autoanalyzer (Technicon RA-1000;
Bayer Co., Tarrytown, NY, USA).
After urine collection, rats were anesthetized with
an intraperitoneal injection of pentobarbital sodium
(30 mg/kg) and placed on a homeothermic table to main-
tain core body temperature at 37◦C, by means of a rectal
probe attached to a homeothermic blanket. Trachea, both
jugular veins, femoral arteries, were catheterized with
polyethylene tubing PE-240 and PE-50. Rats were main-
tained under euvolemic conditions by infusing 10 mL/kg
of body weight of isotonic rat plasma during surgery,
followed by an infusion of 5% polyfructosan, (Inutest;
Laevosan-Gesellschaft, Linz, Austria) or 5% LC sugar
(METCO; Mexico City, Mexico) diluted in 0.9% saline
solution at 1.6 mL/hr. Mean arterial pressure was moni-
tored with a pressure transducer (Model p23 db; Gould,
Hato Rey, Puerto Rico) and recorded on a polygraph
(Grass Instruments, Quincy, MA, USA). Via a midline
abdominal incision, the left renal artery was exposed.
An ultrasound transit-time flow probe (1RB, Transonic,
Ithaca, NY, USA) was placed around the left renal artery
and filled with ultrasonic coupling gel (HR Lubricating
Jelly; Carter-Wallace, New York, NY, USA) for recording
renal blood flow (RBF). After an equilibrium period of
60 minutes, urine was drained from the bladder by grav-
ity via PE-50 tube and collected for 30 to 60 minutes and
blood samples were taken at the beginning and at the end
of the urine collection period.
In order to determine that LC sugar is neither reab-
sorbed nor secreted, the LC sugar linearity of excretion
over a wide plasma concentration range was studied. Af-
ter the surgery, rats were maintained in euvolemic condi-
tions, as was detailed before. Four determinations of GFR
were performed in the same rat by infusing increased con-
centrations of LC sugar that were 5%, 7.5%, 10%, and
12.5%. For each concentration, an equilibrium period of
30 to 45 minutes was allowed and thereafter urine was
drained from the bladder by gravity and collected for 30
to 45 minutes and blood samples were taken at the be-
ginning and at the end of each urine collection period.
GFR evaluation by inutest or LC sugar
Inutest and LC sugar concentrations in urine and
plasma were determined by the Davidson et al [19] modi-
fied technique, which requires the use of anthrone reagent
for determination of fructose. Briefly, anthrone is freshly
prepared at final concentration of 0.08% in diluted sulfu-
ric acid and stored at 4◦C in a dark bottle until its use.
Standard solutions
Stock solutions containing 1 mg per mL of inutest and
LC sugar were prepared. Different dilutions of these
stock solutions were used as standards of inutest and LC
sugar, respectively. The standard set concentrations of LC
sugar were between 10 and 100 lg per milliliter.
Protein-free plasma samples were prepared by adding
250 lL of water and 125 lL of 1.0 N TCA to 20 lL of
plasma. The mixture was shaken, centrifuged, and pro-
tein free supernatant isolated for subsequent analysis.
Urines were diluted for maintaining LC sugar concen-
trations within analytical range (10 to 100 mg per mL).
Anthrone reagent aliquots of 500 lL were placed in
Eppendorff tubes, maintained on ice, and 100 lL of
each sample (standard solution, protein-free plasma or
urine) was added. All tubes were shaken vigorously
and incubated on a water bath at 38◦C for 50 minutes.
The tubes were cooled and the absorbance at 620 nm
was recorded by using a Beckman spectrophotometer.
Appropriate plasma and urine blanks, collected before
inutest or LC sugar infusion, were run in each determi-
nation. All samples from normal and CsA treated rats
were run in duplicate and a set of standards was included
in each determination.
Inutest, LC sugar, and creatinine clearances were cal-
culated by the standard formula C = U ∗ V/P, where U
is the marker concentration in urine, V is urine flow rate,
and P is the marker concentration in plasma.
Statistical analysis
Linear regression and correlation were calculated by
the least-squares method and the values represent mean
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Fig. 1. Representative standard curves for LC sugar concentrations by
using anthrone reagent. Two sets of standards were made. Linear regres-
sion and correlation were calculated by the least-squares method and
the values represent the mean value of each concentration ± standard
deviation.
value ± standard deviation. Results of the quantitative
traits are expressed as mean ± standard error. Statisti-
cal comparisons among experimental groups were per-
formed by using analysis of variance (ANOVA), and for
comparing different experimental periods in the same
group, repeated measures ANOVA was used. When
ANOVA showed a statistically significant difference,
Student–Newman-Keuls test was performed. Statistical
significance for all tests was judged at P < 0.05.
RESULTS
Figure 1 depicts the LC sugar standard concentration
curve. Ten different concentrations varying from 10 to 100
lg/mL were analyzed. Each point represents the mean of
absorbance ± standard deviation of 6 different determi-
nations and shows minimal fluctuations among the per-
formed analysis. LC sugar determined by Davidson et al
[19] technique by using anthrone gives a linear and highly
reproducible standard curve. The correlation coefficient
was 0.9939 and r squared 0.9879. Increased LC sugar con-
centrations showed a linear pattern with respect to ab-
sorbance values. Thus, LC sugar concentration could be
determined by Davidson’s technique by using anthrone
reagent.
LC sugar infusion modified neither MAP nor RBF
when they were compared with their respective controls
infused with inutest. Although CsA treated rats infused
with inutest or LC sugar tended to present minor values
of MAP than nontreated rats (96.4 ± 3 and 92 ± 3.4 mm
Hg, vs. 112.6 ± 2.8 and 109.0 ± 2.4, respectively), there
were no significant differences among the studied groups.
These results can be also seen in Figure 2.
The fall of RBF evidenced that both groups that re-
ceived CsA presented renal dysfunction. In inutest in-
fused rats, RBF for CsA-treated rats was 2.9 ± 0.5 ver-
sus 6.1 ± 0.6 mL/min for nontreated rats. In the same
way, in LC sugar infused rats it was 2.9 ± 0.5 versus 5.9
± 0.6 mL/min, respectively. Thus, similar reduction was
recorded in CsA treated rats infused with inutest or LC
sugar. These results showed that LC sugar infusion did
not alter these physiologic parameters and evidenced that
both groups of CsA presented nephrotoxicity.
Renal creatinine clearance is shown in Figure 3. Non-
treated and CsA treated rats that were used for inutest
infusion had similar renal function that those used for LC
sugar infusion assessed by creatinine clearance. The val-
ues of creatinine clearance in nontreated and CsA treated
rats that were used for inutest infusion were 1.8 ± 0.2 and
0.6 ± 0.1 mL/min, respectively, and for LC sugar infusion
were 1.7 ± 0.3 and 0.7 ± 0.2 mL/min, respectively. These
results also show that CsA-treated rats present renal
dysfunction.
Figure 4 shows the estimation of glomerular filtration
rate by using LC sugar as a marker of GFR compared
with inutest. In nontreated rats, the mean GFR evaluated
with LC sugar was 2.2 ± 0.1. This value was similar to that
obtained with inutest: 2.3 ± 0.1 mL/min. The GFR values
normalized by body weight (BW) were 0.72 ± 0.04 and
0.73 ± 0.05 mL/min/100 BW, respectively.
CsA administration produced a significant reduction of
GFR that was equally determined by both LC sugar and
inutest. GFR in LC sugar infused rats was 1.1 ± 0.2 and
in inutest infused rats was 1.0 ± 0.2 mL/min (P = NS).
The GFR normalized by body weight was 0.36 ± 0.06 and
0.35 ± 0.05 mL/min/100 BW, respectively. In addition, as
we detailed before, the GFR assessed by creatinine clear-
ance was lower than inutest and LC sugar. All these re-
sults indicate that LC sugar is a GFR marker comparable
to the “gold standard” inulin.
Figure 5 depicts the assessment of GFR by using differ-
ent LC sugar concentrations, ranging from 5% to 12.5%.
At the beginning and at the end of each urine recollec-
tion, blood samples were taken to evaluate LC sugar
plasma concentration, and the mean value was used to
estimate GFR in each urine recollection. As expected,
LC sugar plasma concentration gradually raised with in-
creased concentration of LC sugar infusion, as shown
Figure 5A. Each point represents the mean value of the
LC sugar plasma concentrations at the beginning and at
the end of each urine recollection. For LC sugar infusion
at 5% the concentration was 0.4 ± 0.05 mg/mL, for 7.5%
it was 0.7 ± 0.07 mg/mL, for 10% the value was 0.9 ± 0.12
mg/mL, and for 12.5% it was 1.2 ± 0.05 mg/mL. All these
differences were statistically different.
Figure 5B shows that in spite of increased LC sugar
plasma concentration the GFR remained unaltered. The
GFR value obtained with 5% LC sugar infusion was 2.3 ±
0.2 mL/min, with 7.5% it was 2.1 ± 0.1 mL/min, with 10%
the value was 2.1 ± 0.1 mL/min, and finally, the GFR with
12.5% was 2.3 ± 0.5 mL/min. No statistical differences
were observed among the different used concentrations.
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Fig. 2. Mean arterial pressure and renal blood
flow was recorded in nontreated rats (white
bars) and in CsA treated rats (black bars)
infused with inutest or LC sugar as mark-
ers of glomerular filtration rate. The results
are expressed as means ± standard error.
Statistical comparisons between experimen-
tal groups were performed by using ANOVA
and Student–Newman-Keuls test. ∗P < 0.05













Fig. 3. Creatinine clearance in nontreated rats (white circles) and in
CsA treated rats (black circles) that were used in inulin or LC sugar
groups. Individual values are showed in the graph. Horizontal lines rep-
resent the mean value for each group. Statistical comparisons between
experimental groups were performed by using ANOVA and Student–
Newman-Keuls test. ∗P < 0.05 vs. their respective nontreated groups.
DISCUSSION
Here we present an alternative marker of glomeru-
lar filtration rate by using low calorie sugar. Our results
indicate that measurement of LC sugar concentration
in plasma and urine is a useful and accurate marker to
estimate GFR in normal conditions and during renal
dysfunction. The estimation of GFR with LC sugar and
inutest was virtually identical, suggesting that LC sugar
is a sensitive marker of GFR with the advantages that it
is easy to acquire together with its very low cost.
The assessment of glomerular filtration rate (GFR) is
the most commonly used test of renal function. Endoge-
nous markers that are widely used for the estimation of
GFR, such as serum creatinine, are suitable to estimate
renal function in the clinical setting and in subjects with
normal renal function, but are not ideal to determine
GFR in patients with reduced renal function or when an
accurate GFR is required (i.e., experimental models of
renal disease). In consequence, inulin clearance provides














Fig. 4. Inutest and LC sugar were used as markers of glomerular filtra-
tion rate, white circles represent the values of GFR in nontreated rats
and the black circles the GFR values in CsA treated rats. Horizontal
lines represent the mean value for each group. Statistical comparisons
between experimental groups were performed by using ANOVA and
Student–Newman-Keuls test. ∗P < 0.05 vs. their respective nontreated
groups.
for evaluating single nephron GFR in experimental mod-
els of renal disease by using micropuncture techniques.
Thus, inulin is considered as the “gold standard” of re-
nal function evaluation [1–6], but its use is limited for the
requirement of IV infusion.
Inulin concentration is detected through colorimetric
assay by the action of anthrone reagent, which reacts
mainly with fructose and in much lesser proportion with
glucose [20]. The glucose interference was solved by the
modification made by Davidson et al [19], under the con-
dition proposed by these authors; glucose did not react
with anthrone and is almost undetectable by this method.
The present study was undertaken to evaluate the appli-
cation of LC sugar as a new marker of GFR by using
Davidson et al [19] technique.
LC sugar is a patented formula of a food in-
dustry from Mexico (METCO; http://www.metco.com.
mx/azucarbc2.html) isolated from sugar cane. LC sugar
contains mainly sucrose processed with sweeteners.
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Fig. 5. Effect of increasing LC sugar con-
centrations infusion on (A) LC sugar plasma
concentration and (B) glomerular filtration
rate in nontreated rats. Each point repre-
sents mean value from 6 different rats ± stan-
dard error. Statistical comparison was per-
formed by using repeated measures ANOVA
and Student–Newman-Keuls test. ∗P < 0.05
vs. 5% LC sugar infusion period, ∗∗P < 0.05
vs. 7.5% LC sugar infusion period, and ∗∗∗P <
0.05 vs. 10% LC sugar infusion period.
Because sucrose is composed by fructose, we reasoned
that LC sugar could be detected by the Davidson’s modi-
fied technique and that LC sugar in plasma will be freely
filtrated and neither reabsorbed nor secreted. The fact
that LC sugar standard curve showed to be reproducible
and highly lineal, together with the observation that GFR
values detected with LC sugar in rats were similar to
those estimated with inutest, indicate that LC sugar could
be indeed accurately analyzed with anthrone reagent. In
order to know if another sweetener such as Splenda
(Splenda, McNeil Nutritionals, Washington, PA, USA),
which contains maltodextrin and sucralose, but not su-
crose, could be also a GFR marker, some experiments
were performed (data not shown). We observed that an-
throne did not react with the components of Splenda.
Our results also suggest that LC sugar is not secreted
or reabsorbed at tubular level, because if this were the
case, GFR values might would be lesser or greater than
inutest GFR. We observed that when LC sugar plasma
concentration gradually rises, the GFR did not change
(Fig. 5). These results suggest that LC sugar is a solely
GFR-dependent excretion.
It is known that endogenous creatinine can be used
to estimate GFR with reasonably degree of certain in
animal or subjects with normal renal function, but reduc-
tion in renal function is associated with increased tubular
secretion of creatinine. Therefore, as renal dysfunction
progresses, assessment of GFR by creatinine clearance
is less accurate. Thus, to determine if LC sugar could be
used to estimate GFR during renal dysfunction, we used
an animal model of renal failure induced by CsA adminis-
tration [6, 12, 21–23]. In the present study we found a sig-
nificant increased of LC sugar plasma concentrations and
reduction of LC sugar renal clearance in these animals.
The similitude of GFR by LC sugar and inutest in normal
and pathologic conditions suggests that LC sugar is also
a gold standard method for the detection of glomerular
filtration rate.
Assessment of GFR using LC sugar provides 3 dis-
tinctive advantages. One is the incredible low cost per
experiment. In our experience with rats, a typical inulin
experiment costs approximately $10.00, whereas the cost
per rat using LC sugar is $0.002 dollars. Thus, for exam-
ple, a regular manuscript that reports experiments made
on 6 groups of 8 rats each (i.e., 48 rats, without consider-
ing the animals lost along the study) represents a cost of
$480.00 dollars to determine GFR using inutest, in con-
trast with 10 cents using LC sugar. This represents about
a 5000-fold lesser cost per experiment, which certainly
would be convenient in most of the renal research labo-
ratories throughout the world. Second, LC sugar is a safe
compound that does not present the inconveniences as-
sociated with dealing with radioactive compounds. Third,
LC sugar is widely available.
Our results also suggest that LC sugar can potentially
be used in the clinical setting once it will be manufac-
tured for intravenous administration. This assumption,
however, will have to wait until LC sugar is adequately
prepared and proven for use in humans.
CONCLUSION
The data presented here demonstrate that LC sugar
clearance is a convenient, accurate, and accessible marker
to estimate the glomerular filtration rate.
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